|Home | About | Journals | Submit | Contact Us | Français|
Although previous neuroimaging studies suggest that adolescents with bipolar disorder exhibit smaller amygdala volumes compared with healthy adolescents, whether these abnormalities are present at illness onset or instead develop over time remains unclear. The aim of this study was to conduct a prospective longitudinal investigation comparing amygdala neurodevelopment among adolescents following their first manic episode, adolescents with attention deficit hyperactivity disorder (ADHD), and healthy adolescents.
Thirty adolescents hospitalized for their first manic/mixed episode associated with bipolar disorder, twenty-nine adolescents with ADHD, and twenty-four demographically matched healthy teens underwent magnetic resonance imaging scans at index assessment and approximately 12 months later. Adolescents with bipolar disorder were prospectively evaluated using diagnostic interviews and symptom rating scales.
Mixed models examining group-by-time effects for both left (p=0.005) and right (p=0.002) amygdala volumes were statistically significant. Change in left (p=0.01) and right (p=0.0008) amygdala volumes from baseline to 12 months were significantly different among groups. Specifically, left amygdala volumes increased over time in healthy adolescents (p=0.008) and adolescents with ADHD (p=0.0009), but not in adolescents with bipolar disorder (p=0.3). Right amygdala volume increased over time in adolescents with ADHD (p<0.001), but not in healthy adolescents nor in adolescents with bipolar disorder (p=0.1 and p=0.3, respectively). In adolescents with bipolar disorder, baseline total amygdala volume was significantly greater in those who subsequently achieved symptomatic recovery as compared to those who did not achieve recovery (p=0.02).
Adolescents with mania fail to exhibit normal increases in amygdala volume that occur during healthy adolescent neurodevelopment.
The amygdala is involved in emotional processing and through inhibitory connections may also be instrumental in regulating emotion. Therefore, the amygdala may play an important role in the pathophysiology of bipolar disorder.1–4 Indeed, most magnetic resonance imaging (MRI) studies of adolescents with bipolar disorder report smaller amygdala volumes as compared to healthy subjects.5 Moreover, a recent meta-analysis revealed that smaller amygdala volume may be a marker of early- (vs. late) onset bipolar disorder.5 However, most MRI studies of adolescents with bipolar disorder are cross-sectional and include adolescents with bipolar disorder who have been ill for several years, making it difficult to determine whether structural amygdala abnormalities are present at illness onset or develop during the course of illness. Understanding the timeline of structural amygdala changes in bipolar disorder might identify whether this abnormality is a marker of illness onset, and/or a marker associated with illness progression. Additionally, the specificity of amygdala changes in adolescents with bipolar disorder remains unknown since few studies have included a psychiatric comparison group. Although a recent report provided preliminary evidence that volumetric reductions in the amygdala are stable over an interval of approximately two years in ten adolescents and young adults with bipolar disorder, the present report includes a larger and more homogeneous sample of inpatients with bipolar disorder. Additionally, we include a comparison group of adolescents with ADHD to determine the specificity of our findings.6
With these considerations in mind, we compared differences in amygdala volumes among adolescents with bipolar I disorder at their initial manic or mixed episode, adolescents with attention deficit hyperactivity disorder (ADHD), and a group of healthy adolescents at an initial, index assessment, and 12 months later, in order to clarify whether abnormalities in amygdala neurodevelopment occur early in the course of bipolar disorder. Based on previous studies and meta-analyses,5 we hypothesized that amygdala volumes would be smaller in adolescents with bipolar disorder at baseline, as well as at one year following their initial manic episode, as compared to the other two groups.
Adolescents 12 through 17 years of age, experiencing their first mixed or manic episode associated with bipolar disorder (n=30) were recruited from the inpatient units of Cincinnati Children’s Hospital Medical Center (CCHMC). Participants met DSM-IV-TR criteria for a manic or mixed episode associated with bipolar I disorder. Demographically-matched adolescents with ADHD (n=29) and healthy adolescents (n=24) were recruited from community advertisements and were excluded for history of any DSM-IV-TR Axis I disorder (other than ADHD in the former group) in themselves or their first-degree relatives. Psychopathology was assessed using the Family History Research Diagnostic Criteria.7 Study participants were group-matched for age, race, sex, socioeconomic status, and Tanner stage (Table 1). We matched for Tanner stage based on data which suggest that sex steroid hormones exert effects on brain and behavior at puberty and are involved in the reorganization of sensory and association regions of the brain including the visual cortex, amygdala, and hippocampus.8–11
DSM-IV-TR diagnoses were confirmed by trained raters (kappa > 0.9) who administered the Washington University in St. Louis Kiddie Schedule of Affective Disorders and Schizophrenia (WASH-UKSADS). 12 Study participants were excluded by having a history of substance abuse within three months of the index assessment, a lifetime diagnosis of substance dependence, an IQ < 70 on the Wechsler Abbreviated Scales of Intelligence, any contraindication to undergoing an MRI scan, an unstable medical or neurological disorder, a history of head trauma resulting in a loss of consciousness for greater than five minutes, or Tanner stage < 3.13 Adolescents with bipolar disorder were excluded by having exposure to active psychotropic medications (other than antidepressants and psychostimulants) greater than one month cumulative or having a prior hospitalization for a mood episode.
All study participants provided written assent and their legal guardians provided written informed consent after study procedures were fully explained. This study was approved by the University of Cincinnati and the Cincinnati Children’s Hospital Medical Center Institutional Review Boards.
Study participants completed two structural MRI scans, approximately 12 months apart. At the baseline scan, thirty-two subjects (9 bipolar, 10 ADHD, and 13 healthy) underwent an MRI scan at the Cincinnati Children’s Hospital Medical Center’s Imaging Research Center (CCHMC-IRC) on a Bruker Biospec 30/60 3-Tesla MRI scanner (Bruker Medizintechnik, Karisruhe, Germany) equipped with a head gradient radio frequency (RF) coil (Bruker NMR Instruments Inc., Fremont, California). The remaining fifty-one subjects (21 bipolar, 19 ADHD, and 11 healthy ) were scanned at the University of Cincinnati’s Center for Imaging Research (UC-CIR) using a 4-Tesla Varian Unity INOVA Whole Body MRI/MRS system (Varian Inc., Palo Alto, CA) equipped with a head gradient RF coil (MR Instruments Inc., Minneapolis, MN). Twelve months following their initial scan, 29 subjects (7 bipolar, 10 ADHD, and 12 healthy) had their second scan using the CCHMC-IRC MR scanner and 35 subjects (10 bipolar, 14 ADHD, and 11 healthy) had a second scan using the UC-CIR MR scanner. Each subject had a baseline and follow-up scan on the same MRI system.
At each MR session, a high-resolution T1-weighted, 3-D whole brain scan modified driven equilibrium Fourier transform (MDEFT) scan was acquired (CCHMC-IRC parameters: TR/TE=15/4.3 ms, flip angle=20°, FOV=25.6×19.2×19.2 cm and UC-CIR parameters: TR/TE=13/6 ms, flip angle=20°, FOV=25.6×19.2×19.2 cm) 14–15. The voxel size for each scanner was 1mm × 1mm × 1mm. To minimize subject motion during scanning procedures, all subjects were instructed to remain still and foam packing was inserted around their head.
The CCHMC-IRC MRI raw FID data were reconstructed using the Cincinnati Children's Hospital Imaging Processing Software (CCHIPS®), which is specifically tailored to reconstruct Bruker scanner images.16–20 Images were then converted to AFNI format (Analysis of Functional NeuroImages; http://afni.nimh.nih.gov/afni).21 The UC-CIR MRI raw FID data were reconstructed using in-house software developed in IDL (Interactive Data Language), which converts raw FID files into AFNI format. Each MDEFT image was reformatted into the same 3-D space, independent of scanner type, which allowed for consistent viewing of the amygdala boundaries between subjects.
Specifically, the amygdala was measured by identifying the sagittal plane that bisected the left and right cerebral hemispheres in both axial and coronal views in which the posterior commissure was most clearly visualized and the cerebral aqueduct was most patent. The anterior commissure was then identified where the white matter tract was most apparent, just before the fornix. Once these two points were located, AFNI aligned the brain by running a line through the marked points. This line was made parallel to the horizon by rotating the brain to a uniform position from which tracing could better take place. Finally, manual ROI tracing of the amygdala was performed on the reoriented coronal plane by trained raters (MPD, NM) with established high inter- and intra- rater reliability (ICC>0.90) and who were blind to subject identity and group. The left and right amygdalae were traced, separately, based on previously published ROI boundaries.22 Once defined, the volume of each individual ROI was determined through AFNI, by quantifying how many voxels comprised that ROI. ROI volume in cm3 was obtained by multiplying one voxel’s dimensions by the number of voxels in that given ROI. Total brain volume was obtained using standard procedures in AFNI.
Measurements for each ROI (i.e. amygdala and total brain volume) were compared between subjects scanned on each scanner within each group, as well as the entire sample, at each time point. T-tests revealed no statistically significant differences between the region-of-interest (ROI) volume measurements from the two different scanners at each time point (p=0.22 at baseline and p=0.5 at 12 months). Additionally, three (2 bipolar, and 1 healthy) subjects who were scanned at the CCHMC-IRC and sixteen (11 bipolar, and 5 ADHD) subjects who were scanned at the UC-CIR did not complete the second scan; however chi-squared tests revealed no statistically significant differences between the number of subjects who completed both MR scans on the CCHMC scanner versus the CIR scanner within each subject group at twelve months (p=0.7). However, since two different scanners were used, we adjusted for scanner-type in all analyses in order to control for potential scanner effects.
Clinical outcome assessments were administered to participants with bipolar disorder at 1, 4, 8, and 12 months following their index assessment. The index and 12 month clinical assessments were completed within 24 hours of the baseline and follow-up scans.23 At each follow-up visit, trained raters reviewed affective symptoms during the prior interval, week-by-week, with the adolescent and their primary caregiver. Particular attention was given to periods of changing affective symptoms, using the Modified Longitudinal Interval Follow-up Examination (LIFE).24 Each follow-up interview included weekly scores for each item of the symptom ratings scales including: the Young Mania Rating Scale (YMRS) and the Hamilton Rating Scale for Depression (HAM-D).25–27 In addition, an overall rating of symptom severity was made each week based on the scores of the rating and diagnostic instruments using a 1- to 6-point scale (Kappa = 0.92), as previously described.28 LIFE ratings were used to determine symptomatic recovery for each bipolar participant. Symptomatic recovery was defined a priori by at least 8 contiguous weeks with a LIFE overall score of ≤ 2.28–30
Statistical analyses were performed using the Statistical Analysis System (SAS Institute, Cary, NC, USA, 2002–2008). Analyses of variance (ANOVA) and chi-square tests were used to examine group differences in demographic characteristics at each time point. IQ was significantly different among groups at baseline (p=0.001), and was adjusted for in analyses. Total brain volume was not significantly different among groups at baseline nor at 12 months. However, change in total brain volume was significantly different among groups, and therefore, was also used as a covariate to ensure that the changes reported were in amygdala volume, and not the result of total brain volume changes. Finally, scanner-type was adjusted for to minimize potential scanner differences. Group differences in amygdala volumes were analyzed using the MIXED procedure (PROC MIXED) with group, time, and a group-by-time interaction term as the independent variables. Post-hoc analyses examining for differences in amygdala volumes within each group over time as well as among groups at each time point were conducted. Analyses of Covariance (ANCOVA) were used to determine if change in amygdala volume (the difference between the 12 month and baseline volumes) was significantly different among groups.
Information about current and previous psychotropic medications was collected by interviewing the participants and their legal guardians as well as by reviewing medical records. Medication exposure was examined using baseline medications and baseline volume measurements for baseline analyses and medications during the initial 12 months for analyses including change and 12 month measurements. Psychotropic medications were categorized into: psychostimulants, antidepressants, mood stabilizers, and antipsychotics. Analyses of covariance (ANCOVA) were performed to determine if medication exposure was associated with changes in amygdala volume using the ROI as the dependent variable, medication exposure as the independent variable, and IQ and scanner type as covariates.
ANCOVA were used to determine if left and right amygdala volumes at baseline, volumes at 12 months, and change over time were associated with symptomatic recovery using ROI volume as the dependent variable, the presence or absence of symptomatic recovery as the independent variable, and total brain volume as the covariate. Total amygdala volume (the sum of right and left amygdala volumes) was used in order to minimize the number of analyses. Effect sizes were calculated using the formula d = (M1 – M2)/spooled, where d = effect size, M1 – M2 is the difference between mean baseline amygdale volumes or change in amygdala volumes of the subjects within each of the groups (i.e. those with and without symptomatic recovery), and spooled = the pooled standard deviations (SD) of the two groups.31
There were no statistically significant group differences in age, sex, or race among groups at baseline or at 12 months, despite attrition (Table 1). Additionally, there were no statistically significant group differences in time between scans (Table 1). Statistically significant differences in IQ were observed among groups at baseline (p=0.001), but not at 12 months (p=0.06). However, IQ was not correlated with left or right amygdala volume change (R=0.17 and p=0.4; R=0.14 and p=0.5, respectfully). Additionally, there were no differences in findings of volumetric changes with and without controlling for group differences in IQ. Nineteen study participants did not complete the second scan (13 bipolar, 5 ADHD, and 1 healthy; Table 1). There were no statistically significant baseline differences in demographic or clinical variables between subjects who completed 12 months of study participation and subjects who discontinued prior to 12 months. At the baseline scan, 6 (20%) adolescents with bipolar disorder were experiencing a manic episode and 24 (80%) adolescents with bipolar disorder were experiencing a mixed episode. At the second scan, 2 (12%) adolescents with bipolar disorder were experiencing a manic episode and the remaining 15 (88%) adolescents with bipolar disorder were euthymic. Additionally, four of the adolescents with bipolar disorder experienced a second manic episode between their two scans, and one adolescent with bipolar disorder experienced a depressed episode between their scans. However, ANCOVA revealed no significant differences in baseline, 12 month, or change in amygdala volume between those that experienced an additional mood episode and those that did not.
ANCOVA, using all subjects, revealed no statistically significant differences in total brain volume among groups at baseline (F=0.33, df=79, p=0.7) nor at 12 months (F=1.28, df=60, p=0.3; Table 2). There were statistically significant differences in change in total brain volume among groups (F=4.23, df=60, p=0.02). Post-hoc analyses revealed that adolescents with ADHD exhibited a greater increase in total brain volume as compared to adolescents with bipolar disorder (p=0.005). However, change in total brain volume was not significantly different between the healthy adolescents and adolescents with bipolar disorder (p=0.15), nor between the healthy adolescents and adolescents with ADHD (p=0.14).
Mixed models examining group-by-time effects for both left (F=5.7, df=78, p=0.005) and right (F=6.7, df=78, p=0.002) amygdala volumes were statistically significant. Specifically, left amygdala volumes significantly increased over time in the healthy adolescents (12% increase, p=0.008) and adolescents with ADHD (13% increase, p=0.0009), but not in the adolescents with bipolar disorder (p=0.3). Right amygdala volume significantly increased over time in the adolescents with ADHD (16% increase, p<0.001), but not in the healthy comparison group nor in the adolescents with bipolar disorder (p=0.1 and p=0.3, respectively). Therefore, the group-by-time effects in the right amygdala are primarily driven by the significant increase in the adolescents with ADHD and the trend towards an increase in the healthy adolescent group (Figure 1 and Table 2).
ANCOVA revealed that there were statistically significant group differences in volume change from baseline to 12 months, using volume change as the dependent variable, in left (F=5.03, df=59, p=0.01) and right (F=8.07, df=59, p=0.0008) amygdala. Specifically, change in left amygdala volume was significantly different between the adolescents with ADHD and adolescents with bipolar disorder (p=0.007) and the healthy adolescents and adolescents with bipolar disorder (p=0.006). Right amygdala volume change was significantly different between the adolescents with ADHD and adolescents with bipolar disorder (p=0.0002) and healthy adolescents and adolescents with bipolar disorder (p=0.01).
At baseline, ANCOVA revealed no statistically significant differences among groups in left (F=0.23, df=78, p=0.8) nor right (F=1.23, df=78, p=0.3) amygdala volumes. However, at 12 months, there were statistically significant differences among groups in left (F=7.54, df=59, p=0.001) and right (F=7.8, df=59, p=0.001) amygdala volumes. Specifically, left and right amygdala volumes were significantly larger in the healthy adolescents (p=0.0002, p=0.003, respectively) and adolescents with ADHD (p=0.0002, p=0.0002, respectively) than in adolescents with bipolar disorder.
At baseline, there were no statistically significant differences in the left or right amygdala volumes between those subjects who completed both scans, and those who did not (left amygdala, p=0.9 and effect size, Cohen’s d=0.03; right amygdala, p=0.2 and effect size, Cohen’s d=0.2).
Within the adolescents with bipolar disorder, baseline left and right amygdala volumes were significantly correlated with baseline YMRS score (p=0.02, R=0.43 and p=0.02, R=0.41, respectively; Figure 2). Eight of the 30 adolescents with bipolar disorder (27%) had psychosis with their index manic/mixed episode. Although limited due to small sample size, t-tests comparing baseline, follow-up and change in left amygdala, right amygdala, and total brain volumes between those with and without psychosis revealed no statistically significant differences (smallest p value=0.54).
Additionally, at the baseline scan, 15 (50%) adolescents with bipolar disorder were taking an antipsychotic, eight (27%) were taking a mood stabilizer, and one (3%) was taking an antidepressant. Antipsychotics and mood stabilizers had only been taken for less than one month to be included in the study. At the 12 month scan, seven (41%) adolescents with bipolar disorder were on antipsychotics, six (35%) were on mood stabilizers, three (18%) were on psychostimulants, and three (18%) were on antidepressants.
At the baseline scan, 16 (55%) of the adolescents with ADHD were taking a psychostimulant, three (10%) were on an antidepressants, one (3%) was taking an antipsychotic, and one (3%) was taking a mood stabilizer. Two adolescents with ADHD had taken an antipsychotic or a mood stabilizer for less than 1 month. At the 12 month scan, 13 (54%) of the adolescents with ADHD were on psychostimulants, five (21%) were on antidepressants, and one (4%) was on a mood stabilizer.
ANCOVA revealed that medication exposure had no statistically significant effect on amygdala volumes at baseline, 12 months, or volume change over time in adolescents with bipolar disorder. Medication exposure; however, did have a significant effect on volume in adolescents with ADHD. Psychostimulants taken at baseline had a significant effect on right amygdala volume change (p=0.04). In addition, psychostimulants taken at 12-months had a significant effect on right amygdala volume change (p=0.01). In both cases, adolescents with ADHD had a smaller right amygdala volume change if they were taking psychostimulants. Furthermore, adolescents with ADHD taking psychostimulants at 12-months had a significantly smaller left amygdala volume at that scan (p=0.046).
Nine adolescents with bipolar disorder who had a baseline scan achieved symptomatic recovery during follow-up. Eleven adolescents with bipolar disorder who had a baseline scan did not achieve symptomatic recovery during the 12 months of follow-up assessments. ANCOVA revealed that baseline total amygdala volume was significantly greater in those who subsequently achieved symptomatic recovery as compared to those who did not have symptomatic recovery (d=1.34, p=0.02; Figure 3). Post-hoc analyses revealed that both right and left baseline amygdala volumes were significantly greater in those who subsequently achieved symptomatic recovery (d=1.2, p=0.008 and d=1.5, p=0.04, respectively). Additionally, an ANCOVA, using total brain volume change as the covariate, revealed no significant differences between those adolescents with bipolar disorder who achieved symptomatic recovery and those who did not in left amygdala volume change (p=0.8) nor right amygdala volume change (p=0.7).
Six adolescents with bipolar disorder developed substance use disorders during the 12 month follow-up period. Although, there were no statistically significant differences in baseline, year, or change in amygdala volumes between those with and without substance use during follow-up (smallest p=0.2), these findings should be interpreted with caution due to the small sample size.
Consistent with findings from Kalmar and colleagues, who reported abnormal changes in prefrontal regions over time in adolescents with bipolar disorder, our study suggests abnormalities in amygdala development during the first year following the initial manic episode in adolescents with bipolar I disorder.32 Specifically, our results indicate that adolescents with bipolar disorder do not exhibit abnormalities in amygdala volumes at the onset of manic illness. However, adolescents with bipolar disorder failed to exhibit increases in amygdala volumes over the first year following their initial manic episode that were observed in healthy adolescents and adolescents with ADHD during the same time period. Similar to healthy adolescents, adolescents with ADHD showed increases in amygdala volumes, suggesting that abnormal amygdala neurodevelopment may be useful as a marker associated with illness progression for adolescent bipolar disorder. During healthy adolescent brain development, there are visible patterns of growth that take place in the limbic system. For example, prior studies of healthy adolescent neurodevelopment indicate that the temporal lobe structures (amygdala and hippocampus) increase in volume with age.33 Our findings of decreased amygdala volume in adolescents with bipolar disorder at one year, but not at the time of the first manic episode, are consistent with cross-sectional reports of decreased amygdala volumes in adolescents with bipolar disorder, as well as reports indicating that these abnormalities are not present in adolescents at risk for developing bipolar disorder, prior to illness onset.34–41
Although the neurpathological basis for failure to exhibit healthy amygdala growth in bipolar disorder is unknown, it may result from failure to expand the neuronal tree within the amygdala during adolescence or disturbances in the growth of glial cells.41–44 As a part of the ventral-limbic pathway, the amygdala is central in emotional processing, so that incomplete amygdala development in adolescents with bipolar disorder may lead to increased problems for these individuals in adapting responses to emotional and social stimuli.45–51 Indeed, prior studies suggest that adolescents with bipolar disorder exhibit alterations in emotional regulation and in their ability to recognize facial affect.23,52–56 Dysfunction of this pathway, along with the dorsal-subcortical pathway, that modulates cognitive processes, is believed to underlie the neurophysiology of bipolar disorder.36,57–58
One explanation for the differences in amygdala volumes over time may be related to differences among groups in medication exposure. In our analyses, amygdala volumes of adolescents with bipolar disorder did not appear to be significantly affected with medication exposure. However, the amygdale volumes of adolescents with ADHD were significantly associated with psychostimulant use. In contrast to our findings, previous studies report that medication exposure can increase the volume of the hippocampus and the amygdala, and therefore, future medication studies are needed to further support this conclusion.59–61
Greater amygdala volumes at the onset of mania were found in those who subsequently achieved symptomatic recovery. This finding demonstrates that amygdala volume at initial manic episode may be useful as a potential marker of treatment response or a prognostic indicator of clinical outcome. The variability present in the baseline amygdala volumes of the adolescents with bipolar disorder who recovered compared with those who did not might be attributable to other factors including substance use and medication exposure. Future studies examining the impact of these variables on structural and functional brain changes in a larger sample of adolescents with bipolar disorder, over more time points, are required to determine whether specific interventions may influence these associations. Additionally, a larger study employing a receiver operating characteristic (ROC) analysis could help determine whether specific values of amygdala volume provide maximal sensitivity and specificity for predicting outcomes.
There are several limitations that should be considered when interpreting the results of our study. First, the use of two different scanners might have caused discrepancies in ROI volumes. However, multiple steps were taken to ensure comparability. These steps included maintaining the same scanner for each individual for both of that individual’s scans, co-varying for scanner-type during the analyses, and using change in ROI volume as a dependent variable. Additionally, no scanner specific effects were observed. Second, although our study is a prospective study, adolescents and their family members were interviewed retrospectively at each follow up visit, which might have limited their ability to accurately recall mood symptoms. However, in order to improve the accuracy of information obtained, subjects and their primary caregivers were each interviewed. These interviews were performed frequently (at 1, 4, 8, and 12 months) and all subjects were reminded of anchor time points (i.e., holidays, birthdays, and school events) that occurred during each follow up period. Third, IQ significantly differed among the groups, and therefore, was adjusted for in volumetric analyses. However, a correlation between IQ and amygdala volume did not reveal any significant associations, consistent with previously reported findings in healthy adults. 62 Fourth, clinical outcome measures revealed that by 12 months many of the adolescents with bipolar disorder who began the study manic were euthymic (Table 1). Associations revealed a significant correlation between baseline YMRS scores and amygdala volume in the bipolar group; however no correlation was found between 12 month YMRS scores and amygdala volume. Additionally, no correlations were found between HAM-D scores and amygdala volume. The percentage of subjects who did not complete 12 months was greater in adolescents with bipolar disorder (43%) than in adolescents with ADHD (17%) or healthy (4%) adolescents (p<0.0001). However, we examined differences in the demographic and clinical characteristics, as well as the amygdala volumes for those subjects who dropped out and those who completed the study and no statistically significant differences were found. Additionally, we did not systemically collect data regarding stressful life events or trauma that occurred between assessments. However, Post Traumatic Stress Disorder (PTSD) KSADS modules were repeated and no subject developed PTSD during the 12-month follow-up period. Nonetheless, studies examining whether high-stress or trauma impacts the neurodevelopment of bipolar disorder and/or symptomatic recovery are needed. Finally, comparisons made examining relationships between outcome measures and medication exposure with amygdala volumes were likely underpowered due to the small sample sizes.
Nonetheless, despite these limitations, to our knowledge this study is the first to demonstrate abnormal amygdala development in early course bipolar disorder compared with healthy adolescents and adolescents with ADHD. Although there were too few subjects in our sample to examine the impact of prior depressive episodes or co-occurring anxiety disorders, future studies assessing the effects of these factors, as well as family history of mood disorders on amygdala volumes are needed. Furthermore, studies examining whether amygdala volumes at illness onset or changes in amygdala volumes over time are predictive of clinical outcome are also needed. Similarly, long-term prospective studies that investigate whether amygdala changes may be modified with effective medications and whether adults with adolescent onset bipolar disorder exhibit similar amygdala abnormalities into adulthood are necessary to enhance our knowledge about the pathophysiology of bipolar disorder.
Support for this research was provided by the National Institute of Mental Health (NIMH) Grant number: K23 MH63373 (MPD)
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Data from this manuscript were presented, in part, at the 48th Annual Meeting of the American College of Neuropsychopharmacology; 2009 December 6–10, Hollywood, Florida.
Disclosure: Dr. Adler has served on the speakers’ bureau for Merck, and Janssen. He has received research support from Eli Lilly and Co., Janssen, Pfizer, Forrest, AstraZeneca, Bristol-Myers Squibb, Repligen, and Johnson and Johnson. Dr. Strakowski has served as a consultant for Pfizer, Eli Lilly and Co., Tikva, and Dimedix. He has received research support from Pfizer, Eli Lilly and Co., Janssen, AstraZeneca, Martek Biosciences, Nutrition 21, Bristol-Myers Squibb, Somerset, Johnson and Johnson, Forest, Shire, and Repligen. Dr. DelBello has served on the speakers’ bureau or as a consultant for Bristol-Myers Squibb and Merck. She has received research support from AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Co., Forrest, Amylin, GlaxoSmithKline, Pfizer, Janssen, Merck, and Johnson and Johnson, Otsuka and Somerset. Ms. Bitter and Mr. Mills report no biomedical financial interests or potential conflicts of interest.